Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 13 of 966 for:    fibromyalgia

Magnesium, Stress and Fibromyalgia (SeMAFor)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03887000
Recruitment Status : Not yet recruiting
First Posted : March 22, 2019
Last Update Posted : March 22, 2019
Sponsor:
Collaborator:
CIC Inserm 1405, University Hospital Clermont-Ferrand, France
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand

Brief Summary:

Fibromyalgia affects an average of 2% of the French population. Data from the literature report that low levels of magnesium could be associated with fibromyalgia. However, no study to date has investigated the effect of oral magnesium administration on stress in fibromyalgia.

This trial therefore aims to evaluate whether magnesium could improve stress and the various disorders that contribute to the complexity of fibromyalgia, including pain, cognition, sleep disorders and quality of life.


Condition or disease Intervention/treatment Phase
Fibromyalgia Other: magnesium Other: placebo Not Applicable

Detailed Description:

This is an interventional, randomized, placebo-controlled, double blind study of the use of magnesium in fibromyalgia. The effect of magnesium on stress measured by DASS-42 over 28 days after taking magnesium / placebo will be studied.

The secondary objectives will evaluate the evolution of the scores of all the tests and questionnaires carried out before taking magnesium or placebo (D0: Visit 2), then at D0 + 28 (visit 3) and D0 + 84 days (visit 4 corresponding to the end-of-study visit).

Secondary parameters are the following :

Impact of fibromyalgia, heart rate variability, pain intensity, cognition, feelings of patients, impression of change, sleep quality, fatigue intensity, social vulnerability, catastrophism, presence of small fiber neuropathy, concentration of magnesium, analysis of microbiota and evaluation of genetic factor.

Blood magnesium and magnesuria will be measured.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Effect of Magnesium on Stress in Fibromyalgia: Randomized Double-blind Placebo Controlled Trial
Estimated Study Start Date : April 2019
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fibromyalgia
Drug Information available for: Magnesium

Arm Intervention/treatment
Experimental: MAGNESIUM
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
Other: magnesium
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Other: placebo
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Experimental: PLACEBO
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
Other: magnesium
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan

Other: placebo
Fibromyalgia patients taking either magnesium or placebo according to the randomized plan




Primary Outcome Measures :
  1. Measure of stress with DASS-42 [ Time Frame: at day 0 ]
    Measure of stress with stress subscale in magnesium and placebo group. This subscale consists of 14 questions of self-evaluation


Secondary Outcome Measures :
  1. Evaluation of the impact of fibromyalgia using the FIQ questionnaire [ Time Frame: Day0; Day0+28; Day0+84 ]
    The revised FIQ questionnaire is a 10-item self-questionnaire that assesses the impact of fibromyalgia

  2. Detection of fibromyalgia using the FIRST questionnaire [ Time Frame: Day0; Day0+28; Day0+84 ]
    The FIRST questionnaire is a 6-item self-questionnaire that detects fibromyalgia.

  3. Evaluation of stress by the heart rate variability [ Time Frame: Day0-7; Day0; Day0+28; Day0+84 ]
    Heart rate variability (HRV / HRV) is a measure of changes in heart rate that will provide an estimate of stress. It is usually calculated by analyzing time series of beat-by-beat intervals of the ECG or blood pressure plots.

  4. Assessment Using Numerical Scale (EN) [ Time Frame: Day0; Day0+28; Day0+84 ]
    This scale allows the patient to note the pain on a graduation whose minimum score is 0 and the maximum score is 10.

  5. Concise Pain Questionnaire (QCD) [ Time Frame: Day0; Day0+28; Day0+84 ]
    This self-assessment scale allows the patient to characterize the pain in relation to its psychosocial intensity and impact. The patient is asked to answer 9 graduated questions by circling a number from 0 (no pain) to 10 (the most horrible pain you can imagine).

  6. Evaluation of the impact on cognition by the Trail Making Test A and B (TMT A and B) and the Cantab® test [ Time Frame: Day0; Day0+28; Day0+84 ]

    The Trail Making Test (TMT) is recognized as one of the most frequently used neuropsychological tests in clinical practice alternating numbers and letters (1-A-2-B-3- C, etc.).

    The Cantab® is a comprehension test, executive functions, memory, attention and decision-making.


  7. Evaluation of the impact on cognition by the Trail Making Test A and B (TMT A and B) [ Time Frame: Day0; Day0+28; Day0+84 ]
    The Trail Making Test (TMT) is recognized as one of the most frequently used neuropsychological tests in clinical practice alternating numbers and letters (1-A-2-B-3- C, etc.).

  8. Cantab® test [ Time Frame: Day0; Day0+28; Day0+84 ]
    The Cantab® is a comprehension test, executive functions, memory, attention and decision-making.

  9. Evaluation of the emotions by visualization of images and scale evaluating the feelings of the patients [ Time Frame: Day0; Day0+28; Day0+84 ]
    The International Affective Picture System (IAPS) is a library of 1200 standardized images that can induce an emotional reaction, constituting as many emotional stimuli (positive or negative) or not (neutral).

  10. Evaluation of the overall impression of change by the Patient Global Impression of Change Questionnaire (PGIC) [ Time Frame: Day0; Day0+28; Day0+84 ]
    The Global Impression of Change Patient is a scale of global perception of change ("deterioration" or "improvement") completed by the patient. This scale is graduated from 1 = much better to 7 = significantly worse

  11. Evaluation of the impact on the Pittsburg Sleep Quality Index (PSQI) [ Time Frame: Day0; Day0+28; Day0+84 ]
    The Pittsburg Sleep Quality Index is a self-administered questionnaire with 19 items. It has been developed to measure the quality of sleep in the month preceding the interview with the patient. This questionnaire has 7 components: subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disorders, use of a sleep medication, and poor daytime fitness

  12. Evaluation of the intensity of fatigue by the Fatigue Severity Scale (FSS) [ Time Frame: Day0; Day0+28; Day0+84 ]
    The fatigue severity scale is a 9-item self-questionnaire to assess the patient's fatigue intensity. The patient is asked to circle a number from 1 to 7 for each question, a low value representing a low intensity

  13. Social Vulnerability Assessment (EPICES) [ Time Frame: Day0; Day0+28; Day0+84 ]
    The EPICES questionnaire is composed of 11 binary questions (yes / no) allowing to calculate an individual score indicating the precariousness and inequalities of health ranging from 0 to 100.

  14. Evaluation of catastrophism by the PCS (Pain Catastrophizing Scale) scale [ Time Frame: Day0; Day0+28; Day0+84 ]
    Pain Catastrophizing Scale (PCS) is a questionnaire in which the patient is asked to describe the kind of thought and emotions they feel during pain. This questionnaire consists of 13 items describing different thoughts or emotions that may be associated with the pain. The patient will have to indicate how much he has these thoughts or emotions when he feels pain by giving a score between 0 and 4, 0: not at all, 4: all the time. The final score is the sum of the scores for each question.

  15. Quality of life (Short Form 12 items Short Form survey) [ Time Frame: Day0; Day0+28; Day0+84 ]
    assessed by a quality of life questionnaire (Short Form 12 items Short Form survey (SF12)

  16. Evaluation of the presence of small fiber neuropathy (Sudoscan® ) [ Time Frame: AT Day0; Day0+28 ]
    Sudoscan® (Impeto Medical, Paris, France) is a new device that provides a rapid, non-invasive and reproducible quantitative assessment of sweat function.

  17. Evaluation of the presence of small fiber neuropathy (skin biopsy) [ Time Frame: at Day0 ]
    A skin biopsy will be realized for histological analysis to determine the presence of small fiber neuropathy.

  18. plasma magnesium dosage [ Time Frame: D0; D0+28; D0+84 ]
    The intracellular magnesium concentrations will be determined by the blood samples taken at the inclusion visit, at the end of the treatment on visit 3 (D0 + 28) and on visit 4 (D0 + 84).

  19. erythrocyte magnesium dosage [ Time Frame: D0; D0+28; D0+84 ]
    The erythrocyte magnesium concentrations will be determined by the blood samples taken at the inclusion visit, at the end of the treatment on visit 3 (D0 + 28) and on visit 4 (D0 + 84).

  20. urinary magnesium dosage [ Time Frame: D0; D0+28; D0+84 ]
    The urinary concentration of magnesium will be determined by the urine collected for 24 hours, the day before visits 3 and 4.

  21. urinary magnesium dosage [ Time Frame: D0+28; D0+84 ]
    The urinary concentration of magnesium will be determined by the urine collected for 24 hours, the day before visits 3 and 4.

  22. creatinine dosage [ Time Frame: D0-7 ]
    The creatinine concentrations will be determined by the blood samples taken at the inclusion visit.

  23. Analysis of the microbiota (stool samples) [ Time Frame: 24 hours before the visit 2 ]
    Analysis of the microbiota: the patient must carry out the collection at her home maximum 24 hours before the visit 2 by following the technical instructions described in the explanatory note that will be provided. She will then ensure that the stool preservation and transport procedure described in this document is followed.

  24. Evaluation of genetic polymorphism using OpenArray technology [ Time Frame: Day0-7 ]
    Identification of genes involved



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient over the age of 18,
  • Patient with fibromyalgia according to the criteria of the 2016 ACR,
  • Patient presenting a score on the DASS-42 > 18 scale,
  • Patient free from any initiation of new treatment or diet at the time of inclusion,
  • Cooperation and understanding sufficient to comply with the requirements of the study,
  • Acceptance to give written consent,
  • Affiliation to the French Social Security system,
  • Registration or acceptance of registration in the National Register of Volunteers participating in research.

Exclusion Criteria:

  • having a contraindication to the administration of magnesium: hypersensitivity to magnesium chloride, or to any of the excipients,
  • with a magnesium concentration of > 1.05 mmol / l,- with severe renal impairment with a creatinine clearance < 30 ml / min,
  • receiving a treatment or dietary supplement containing magnesium at the time of inclusion,
  • treated with antibiotics in the three months prior to inclusion,- who has reported gastroenteritis in the two months prior to inclusion,
  • physically unfit to place the palms or soles of the feet on the Sudoscan® electrodes,
  • having a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test (in particular a disease known to cause small fiber neuropathies: diabetes, Sjögren's disease, vasculitis, sarcoidosis, chronic ethylism ....),
  • using anticoagulant therapy or allergy to local anesthetics,- of childbearing age not using an effective contraceptive method, pregnant or breastfeeding woman.
  • participating in another clinical trial, or being in the exclusion period, or having received a total amount of benefits exceeding EUR 4500 over the 12 months preceding the start of the trial,
  • having cooperation and understanding that does not allow strict compliance with the conditions laid down in the Protocol,
  • benefiting from a measure of legal protection (guardianship, guardianship, deprivation of liberty, safeguard of justice),
  • not affiliated to the French Social Security system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03887000


Contacts
Layout table for location contacts
Contact: Lise LACLAUTRE 04 73 75 49 63 drci@chu-clermontferrand.fr

Locations
Layout table for location information
France
Chu Clermont-Ferrand Not yet recruiting
Clermont-Ferrand, France, 63003
Contact: Lise LACLAUTRE    04 73 75 49 63    drci@chu-clermontferrand.fr   
Principal Investigator: Gisèle PICKERING         
Sub-Investigator: Claude DUBRAY         
Sub-Investigator: Christian DUALE         
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
CIC Inserm 1405, University Hospital Clermont-Ferrand, France
Investigators
Layout table for investigator information
Principal Investigator: Gisèle PICKERING University Hospital, Clermont-Ferrand

Layout table for additonal information
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT03887000     History of Changes
Other Study ID Numbers: CHU-429
2018-A02059-46 ( Other Identifier: 2018-A02059-46 )
First Posted: March 22, 2019    Key Record Dates
Last Update Posted: March 22, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University Hospital, Clermont-Ferrand:
Fibromyalgia
Stress
Magnesium
Sleep disorders

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases